Paquinimod
- Generic Name
- Paquinimod
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N2O3
- CAS Number
- 248282-01-1
- Unique Ingredient Identifier
- HB76GLG27V
- Background
Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide. The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.
Systemic Sclerosis Pipeline Shows Promise with 50+ Therapies in Development
• Over 50 active players are currently developing more than 50 pipeline therapies for the treatment of Systemic Sclerosis, indicating a robust and active research landscape.
• Key companies like Eicos Sciences, Kyowa Kirin, and Corbus Pharmaceuticals are advancing Systemic Sclerosis therapies, contributing to a competitive market.
• Promising therapies such as GS-248, KHK4827, and Paquinimod are in various stages of clinical development, offering potential new treatment options.
• Horizon Pharma initiated a Phase 2 clinical trial for HZN-825 BID, with an extension trial for participants completing the initial 52-week treatment period.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath